Russia has announced a major medical breakthrough with the development of a new mRNA-based cancer vaccine named Enteromix. The vaccine was unveiled by Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), during the Eastern Economic Forum.
Developed by the National Medical Research Radiological Centre and the Engelhardt Institute of Molecular Biology, Enteromix has shown high efficacy in preclinical trials. According to Skvortsova, the trials demonstrated a significant reduction in tumor size, with rates ranging from 60% to 80% in test subjects. In some cases, researchers even observed complete tumor regression. Importantly, no serious side effects were reported.
Enteromix is designed as a personalized treatment, using artificial intelligence to analyze a patient’s specific cancer profile and tailor the vaccine to their unique needs. The technology, similar to that used in some COVID-19 vaccines, trains the body’s immune system to identify and attack cancer cells.
While the vaccine’s initial focus will be on colorectal cancer, a version is also in advanced development for glioblastoma (a highly aggressive brain tumor) and certain types of melanoma.
Once regulatory approval is granted, the vaccine will be distributed to Russian citizens free of charge, marking a potentially transformative step in the country’s fight against cancer and a significant leap forward in the field of personalized medicine.
